PBMD Immutep Limited

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Dated October 2, 2015

Commission File Number 001-35428

 

 

PRIMA BIOMED LTD

(Exact Name as Specified in its Charter)

 

 

N/A

(Translation of Registrant’s Name)

Level 7, 151 Macquarie Street

Sydney, 2000 New South Wales, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):  ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨            No   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

 

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 2, 2015

 

 

2

---

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.1		Prima BioMed Appendix 3Y Change of Director’s Interest Notice
99.2		Prima BioMed Appendix 3Y Change of Director’s Interest Notice
99.3		Prima BioMed Appendix 3B & Cleansing Notice

 

3

Exhibit 99.1

 

Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity PRIMA BIOMED LIMITED (ASX:PRR) ABN 90 009 237 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Marc Voigt Date of last notice 5 August 2015 Part 1—Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 1 October 2015 + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

---

 

Appendix 3Y Change of Director’s Interest Notice No. of securities held prior to change 1) Ordinary Fully Paid Shares Shares Options Direct 7,536,666 1,171,754 Indirect — Total 7,536,666 1,171,754 2) American Depositary Receipts (ADR) Shares Options Direct 150—Indirect — Total 150—1 ADR = 30 Ordinary Shares 3) 4,068,627 STI Performance Rights and 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM. 4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015. Class Ordinary Fully Paid Shares Number acquired 1) Ordinary Fully Paid Shares Shares Options Direct 4,068,627—Indirect — Total 4,068,627— Number disposed 4,068,627 Performance Rights Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil The Performance Rights were issued pursuant to the Company’s Executive Incentive Plan in accordance with shareholder’s approval obtained at the Annual General Meeting on 14 November 2014. No amount is payable upon exercise of the Performance Rights for shares after vesting. + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 + See chapter 19 for defined terms.01/01/2011 Appendix 3Y Page 2

---

 

Appendix 3Y Change of Director’s Interest Notice No. of securities held after change 1) Ordinary Fully Paid Shares Shares Options Direct 11,605,293 1,171,754 Indirect — Total 11,605,293 1,171,754 2) American Depositary Receipts (ADR) Shares Options Direct 150—Indirect — Total 150— 3) 12,254,902 LTI Performance Rights in accordance with shareholder approval obtained at 2014 AGM. 4) 13,333,334 Performance Rights in accordance with shareholder approval obtained at the Extraordinary General Meeting on 31 July 2015. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 1) Acquiring 4,068,627 shares upon exercise of the Short Term Incentive performance rights. One ordinary fully paid share was acquired for each Performance Right that vested. Part 2 - Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed + See chapter 19 for defined terms.01/01/2011 Appendix 3Y Page 3

---

 

Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? + See chapter 19 for defined terms. Appendix 3Y Page 4 01/01/2011

Exhibit 99.2

 

Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity PRIMA BIOMED LIMITED (ASX:PRR) ABN 90 009 237 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Pete Meyers Date of last notice 28 November 2014 Part 1—Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 1 October 2015 No. of securities held prior to change 1) 1,715,686 Ordinary Fully Paid Shares 2) 6,004,902 Performance Rights Class 1) Ordinary Fully Paid shares 2) Performance Rights Number acquired 2,573,529 Ordinary Fully Paid Shares Number disposed 2,573,529 Performance Rights + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

---

 

Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil The Performance Rights are issued as remuneration for services as a director as Mr Meyers is taking his fees entirely in Performance Rights in lieu of cash and in accordance with shareholder’s approval obtained at Annual General Meeting on 14th November 2014. No amount is payable upon exercise of the Performance Rights for shares after vesting. No. of securities held after change 1) 4,289,215 Ordinary Fully Paid Shares 2) 3,431,373 Performance Rights Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 1) Acquiring 2,573,529 shares upon exercise of the second tranche of performance rights. One ordinary fully paid share was acquired for each Performance Right that vested. Part 2 - Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2

---

 

Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3

Exhibit 99.3

 

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 1 October 2015 Appendix 3B & Cleansing Notice SYDNEY, AUSTRALIA—Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) Prima advises that 6,335,253 ordinary shares have been issued following the vesting and exercise of 6,335,253 Short Term Incentive performance rights (“STIs”). Vesting of the STIs were contingent on the achievement of performance and employment retention conditions set for executives for the 2014-15 financial year. Due to some executives not meeting all vesting conditions, 2,008,823 STIs lapsed. 4,068 627 have been issued to CEO & Executive Director, Mr. Marc Voigt following the vesting and exercise of his STIs after the achievement of his vesting conditions. Mr Voigt’s performance rights were issued in accordance with shareholder approval received on 14th November 2014. The Appendix 3B also includes the exercise and vesting of performance rights for Mr. Pete Meyers relating to his service as a Non-Executive Director of the company. These performance rights were issued in accordance with shareholder approval received on 14th November 2014. Additionally, please be advised of the issue of 800,000 performance rights issued in accordance with the Executive Incentive Plan granted as Long Term Incentives. In relation to the above issuances as further detailed in the attached Appendix 3B, the Company gives notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (the “Corporations Act”) that: 1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act; 2. as at the date of this notice the Company has complied with: (a) the provisions of Chapter 2M Corporations Act as they apply to the Company; and (b) section 674 Corporations Act; and 3. As at the date of this notice there is no “excluded information” (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company. Yours faithfully Prima BioMed Ltd Deanne Miller General Counsel & Company Secretary Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5 Appendix 3B New issue announcement, application for quotation of additional securities and agreement Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005. Name of entity Prima BioMed Ltd (Company) ABN 90 009 237 889 We (the entity) give ASX the following information. Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space). 1 +Class of +securities issued or to be issued Ordinary Shares Ordinary Shares Ordinary Shares Performance Rights 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 6,335,253 Ordinary Shares 4,068,627 Ordinary Shares 2,573,529 Ordinary Shares 800,000 Performance Rights Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

3 Principal terms of the +securities (e.g., if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) a) Pari passu with existing Ordinary Shares (PRR) b) Pari passu with existing Ordinary Shares (PRR) c) Pari passu with existing Ordinary Shares (PRR d) 800,000 Performance Rights granted as Long Term Incentives (“LTIs”) have been issued under the Executive Incentive Plan as follows: • Performance rights are granted as LTIs subject to meeting vesting conditions of total shareholder return criteria being achieved and continued employment till 1 October 2017 for 75% of these LTIs and till 1 October 2018 for 25% of these LTIs. • On vesting of LTIs, shares will be issued for no consideration. 4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment a) Yes (PRR) b) Yes (PRR) c) Yes (PRR) (a) d) Yes, if/when the Performance Rights vest to shares. (b) 5 Issue price or consideration Nil Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) a) Issued upon vesting of unlisted performance rights issued on 19 September 2014 and 5 August 2015 pursuant to the Prima BioMed Limited Executive Incentive Plan for the 2014 Short term Incentive offer following achievement of the retention performance condition. b) Issued upon vesting of unlisted performance rights issued on 19 September 2014 pursuant to the Prima BioMed Limited Executive Incentive Plan relating to Mr Marc Voigt, subject to shareholder approval received at the AGM on 14 November 2014. c) Mr Pete Meyers exercises 2nd tranche of his performance rights which vested to him i.e. 2,573,529 to convert to ordinary shares, in accordance with shareholder approval received at the AGM on 14 November 2014. d) Performance Rights are issued to employee under the Executive Incentive Plan. 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i Yes, although these securities are not being issued under Listing Rule 7.1A 6b The date the security holder resolution under rule 7.1A was passed 14 November 2014 6c Number of +securities issued without security holder approval under rule 7.1 Not applicable 6d Number of +securities issued with security holder approval under rule 7.1A Not applicable 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 4,068,627 ordinary shares are issued on exercise of performance rights approved for Mr Voigt at the AGM on 14 November 2014. 2,573,529 ordinary shares are issued on exercise of 2nd tranche out of 7,720,588 performance rights approved for Mr Meyers at the AGM on 14 November 2014. Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

6f Number of +securities issued under an exception in rule 7.2 6,335,253 ordinary shares under exception 9(b) 800,000 performance rights 6g If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation. Not applicable 6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements Not applicable 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements Refer Annexure 1 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 1 October 2015 Number +Class 8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable) 1,987,275,427 Ordinary fully paid shares (ASX: PRR) 77,378,696 Options exercisable at $0.20 on or before 19 June 2017 (PRRO) Number +Class—Options 9 Number and +class of all Amount Exercise Price Expiration Date 740,741 $0.3390 1 February 2016 200,000 $0.1730 20 February 2016 1,515,752 $0.0774 30 June 2018 165,116 $0.0774 30 June 2018 Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

147,628,500 $0.05019 12 December 2018 371,445,231 $0.0237 4 August 2020 8,475,995 $0.025 4 August 2025 Number +Class – Performance Rights Amount Type Expiration Date 30,918,333 LTI 30 October 2018 31,333,333 PRs Each tranche of PRs will expire 30 days from each tranche vesting date indicated in this appendix 3B released on 5 August 2015 3,431,373 NED PRs Each tranche of NED PRs will expire 30 days from each tranche vesting date indicated in this appendix 3B released on 26 November 2014. 13,750,828 Convertible Notes each with a face value of AU$1, expiring on 4 August 2025 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) Unchanged Part 2 - Bonus issue or pro rata issue 11 Is security holder approval required? Not applicable 12 Is the issue renounceable or non-renounceable? Not applicable 13 Ratio in which the +securities will be offered Not applicable 14 +Class of +securities to which the offer relates Not applicable 15 +Record date to determine entitlements Not applicable 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? Not applicable Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

17 Policy for deciding entitlements in relation to fractions Not applicable 18 Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. Not applicable 19 Closing date for receipt of acceptances or renunciations Not applicable 20 Names of any underwriters Not applicable 21 Amount of any underwriting fee or commission Not applicable 22 Names of any brokers to the issue Not applicable 23 Fee or commission payable to the broker to the issue Not applicable 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders Not applicable 25 If the issue is contingent on +security holders’ approval, the date of the meeting Not applicable 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled Not applicable 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders Not applicable 28 Date rights trading will begin (if applicable) Not applicable Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

29 Date rights trading will end (if applicable) Not applicable 30 How do +security holders sell their entitlements in full through a broker? Not applicable 31 How do +security holders sell part of their entitlements through a broker and accept for the balance? Not applicable 32 How do +security holders dispose of their entitlements (except by sale through a broker)? Not applicable 33 +Despatch date Not applicable Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities 34 Type of securities (tick one) (a) x Securities described in Part 1 (b) ¨ All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents 35 ¨ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

36 ¨ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1—1,000 1,001—5,000 5,001—10,000 10,001—100,000 100,001 and over 37 ¨ A copy of any trust deed for the additional +securities Entities that have ticked box 34(b) 38 Number of securities for which +quotation is sought Not applicable 39 Class of +securities for which quotation is sought Not applicable 40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Not applicable 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) Not applicable Number +Class Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

42 Number and +class of all +securities quoted on ASX (including the securities in clause 38) Not applicable Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Quotation agreement 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides. 2 We warrant the following to ASX. • The issue of the +securities to be quoted complies with the law and is not for an illegal purpose. • There is no reason why those +securities should not be granted +quotation. • An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act. Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted. • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted. 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement. 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete. Sign here: . Date: 1 October 2015 Company secretary Print name: Deanne Miller Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Appendix 3B – Annexure 1 Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities Introduced 01/08/12 Amended 04/03/13 Part 1 Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate “A”, the base figure from which the placement capacity is calculated Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue 1,228,709,341 Add the following: • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: • Include only ordinary securities here – other classes of equity securities cannot be added • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items 758,566,086 Subtract the number of fully paid +ordinary securities cancelled during that 12 month period Nil “A” 1,987,275,427 Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Step 2: Calculate 15% of “A” “B” 0.15 [Note: this value cannot be changed] Multiply “A” by 0.15 298,091,314 Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items Nil “C” Nil Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1 “A” x 0.15 Note: number must be same as shown in Step 2 298,091,314 Subtract “C” Note: number must be same as shown in Step 3 Nil Total [“A” x 0.15] – “C” 298,091,314 [Note: this is the remaining placement capacity under rule 7.1] Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Part 2 Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate “A”, the base figure from which the placement capacity is calculated “A” Note: number must be same as shown in Step 1 of Part 1 1,987,275,427 Step 2: Calculate 10% of “A” “D” 0.10 Note: this value cannot be changed Multiply “A” by 0.10 198,727,543 Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: •This applies to equity securities – not just ordinary securities •Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed •Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained •It may be useful to set out issues of securities on different dates as separate line items Nil “E” Nil Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889

---

 

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A “A” x 0.10 Note: number must be same as shown in Step 2 198,727,543 Subtract “E” Note: number must be same as shown in Step 3 Nil Total [“A” x 0.10] – “E” 198,727,543 Note: this is the remaining placement capacity under rule 7.1A Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000 Phone: +61 2 9276 1224 Fax: +61 2 8569 1880 www.primabiomed.com.au ABN: 90 009 237 889